Date:3/28/2011

hese forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning.  The performance and financial results of Cephalon or ChemGenex could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing the relevant company such as those set forth in its recent filings with the U.S. Securities and Exchange Commission or other applicable regulatory authorities.  Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect.  Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, neither Cephalon nor ChemGenex intend to update publicly any forward-looking statement, except as required by law . The Private Securities Litigation Reform Act of 1995 permits this discussion.Cephalon Contacts:United StatesMedia:Investor Relations: Natalie de Vane

Chip Merritt+1 610-727.6536 (office)

+1 610-738-6376 (office)ndevane@cephalon.com

cmerritt@cephalon.comFritz Bittenbender

Joe Marczley+1 610-883-5885 (office)

+1 610-883-5894 (office)fbittenb@cephalon.com

jmarczley@cephalon.comAustraliaDavid Petrie/Michael GregoryMerrill Lynch+61 (0)3 9659 2816/+61 (0)3 9659 2343   ChemGenex Contacts:AustraliaChemGenex Information:Investor Relations: Dr. Greg Collier

Rebecca WilsonCEO and Managing Director

Buchan Consulting+61 419 897501 (cell Australia)

+61 (0)3 9866 4722 (office)+1 650 200 8145 (cell USA)

+61 (0)417 382 391 (cell)gc
'/>"/>

SOURCE Cephalon, Inc.; ChemGenex Pharmaceuticals Limited Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. Cephalon Wins FENTORA Patent Suit Against Watson
2. Cephalon Announces Definitive Agreement to Acquire Gemin X
3. Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
4. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
5. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
6. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
7. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
8. Cephalon to Webcast Investor Day
9. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
10. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
11. Cephalon Exercises its Option to Acquire BioAssets Development Corporation